FDA Class II Recall: Zydus Pharmaceuticals' Chlorpromazine Hydrochloride Impacted by Nitrosamine Impurity
Zydus Pharmaceuticals (USA) Inc. has initiated a Class II recall (D-0361-2025) for Chlorpromazine Hydrochloride Tablets, USP 10 mg, distributed nationwide across the U.S. This voluntary action stems from CGMP deviations, specifically the presence of N-Nitroso-Desmethyl Chlorpromazine impurity exceeding interim limits. This event mandates immediate review of supply chain resilience for Chlorpromazine Hydrochloride and highlights the persistent risk of nitrosamine contamination in pharmaceutical manufacturing, impacting procurement and regulatory strategies.
FDA Identifies CGMP Deviations Leading to Chlorpromazine Hydrochloride Recall
Zydus Pharmaceuticals (USA) Inc. has initiated a Class II recall, designated D-0361-2025, for specific lots of its Chlorpromazine Hydrochloride Tablets, USP 10 mg. This critical action, initiated on April 3, 2025, and reported on April 16, 2025, is a direct consequence of identified Current Good Manufacturing Practice (CGMP) deviations. Specifically, the FDA's findings indicate the presence of N-Nitroso-Desmethyl Chlorpromazine impurity at levels exceeding the recommended interim limit. For procurement directors, this means an immediate disruption to the supply chain for a crucial antipsychotic medication. The presence of a nitrosamine impurity, even at interim limits, signals a fundamental breakdown in quality control processes at the manufacturing level, posing significant risks to product integrity and patient safety. Regulatory affairs heads must recognize that such CGMP deviations, particularly involving genotoxic impurities, are a high-priority area for the FDA, often leading to escalated enforcement actions beyond a recall if not adequately addressed. This event necessitates a thorough review of your supplier qualification programs and incoming material testing protocols to ensure similar risks are not present within your own supply network, especially for products sourced from third-party manufacturers.
Zydus's Global Manufacturing and U.S. Distribution Network Impacted
The recalled Chlorpromazine Hydrochloride Tablets, USP 10 mg, are manufactured by Zydus Lifesciences Ltd. in Baddi, India, and distributed within the United States by Zydus Pharmaceuticals (USA) Inc., based in Pennington, NJ 08534. This dual-entity structure highlights the complexities of global pharmaceutical supply chains. The product is identified under Application Number ANDA213368, indicating its status as an approved generic drug. For supply chain VPs, this event underscores the inherent risks associated with offshore manufacturing facilities, particularly concerning CGMP compliance and impurity control. A manufacturing lapse in India directly impacts product availability and regulatory standing in the U.S. market. The recall affects a significant quantity: 3144 bottles, each containing 100 tablets, from Lot #: Z400069, with an expiration date of December 31, 2025. This specific lot number and expiration date are critical for identifying affected inventory across the distribution network. Business development executives should note that such manufacturing issues can erode market confidence and create opportunities for competitors with more robust quality systems or geographically diversified manufacturing footprints.
Extensive U.S. Market Exposure for Recalled Chlorpromazine Hydrochloride
The distribution pattern for the affected Chlorpromazine Hydrochloride Tablets, USP 10 mg, is extensive, covering a nationwide footprint within the U.S. Specifically, the product was distributed across at least 17 states: Mississippi, Alabama, Tennessee, Vermont, Ohio, North Dakota, Minnesota, Wisconsin, South Carolina, Arkansas, Florida, Indiana, Louisiana, New Jersey, Arizona, Texas, Kentucky, and Pennsylvania. This broad reach means that healthcare providers, pharmacies, and distributors across a substantial portion of the U.S. market are directly impacted by this Class II recall. For procurement directors, this necessitates an immediate and comprehensive assessment of current inventory levels and orders for Chlorpromazine Hydrochloride from Zydus Pharmaceuticals (USA) Inc. The recall of 3144 bottles, each containing 100 tablets, from Lot Z400069, represents a tangible loss of available product in the market. Supply chain VPs must activate contingency plans to identify and secure alternative sources to prevent potential stock-outs and ensure continuity of care for patients relying on this medication. The financial implications extend beyond the cost of the recalled product, encompassing logistical expenses for returns and potential penalties for supply disruptions.
Strategic Imperatives for Alternative Chlorpromazine Hydrochloride Sourcing
Given the Class II recall of Chlorpromazine Hydrochloride Tablets, USP 10 mg, due to CGMP deviations and nitrosamine impurity, procurement directors must prioritize the identification and qualification of alternative suppliers. While specific alternative suppliers for Chlorpromazine Hydrochloride are not detailed in current intelligence, this situation underscores the critical need for proactive risk mitigation. Supply chain VPs should immediately initiate a comprehensive review of their approved vendor lists and explore new potential manufacturers, focusing on those with robust quality management systems and a proven track record of FDA compliance. The qualification timeline for a new API or finished drug product supplier can range from 6 to 18 months, depending on regulatory requirements and internal validation processes. Therefore, delaying this process is not an option. Business development executives should consider opportunities to partner with manufacturers demonstrating superior quality and regulatory adherence, potentially diversifying their product portfolio and reducing reliance on single-source origins. This event serves as a stark reminder that supplier diversification is not merely a best practice but a commercial imperative to ensure uninterrupted supply and regulatory compliance.
Heightened Regulatory Scrutiny on Nitrosamine Impurities and CGMP Compliance
While the available intelligence does not detail a prior history of Warning Letters or 483s specifically for Zydus Pharmaceuticals (USA) Inc. or Zydus Lifesciences Ltd. concerning Chlorpromazine Hydrochloride, this Class II recall due to CGMP deviations is a significant regulatory event. The presence of N-Nitroso-Desmethyl Chlorpromazine impurity highlights the FDA's ongoing and intensified focus on nitrosamine contamination across the pharmaceutical industry. This isn't an isolated incident; recent parallel events, such as Essential Wellness Pharma's progesterone injection recall for sterility issues and FDA hearings impacting Amgen's Tavneos, signal a broader trend of rigorous regulatory oversight. For regulatory affairs heads, this means that even a 'voluntary: firm initiated' recall, as in this case, does not diminish the severity of the underlying CGMP failure. It signals a need for all manufacturers and distributors to re-evaluate their risk assessments for nitrosamine formation, particularly in older molecules or processes that may not have been initially designed with current impurity profiles in mind. Proactive engagement with regulatory guidance on nitrosamines is paramount to avoid similar, or more severe, enforcement actions.
Remediation Pathways and Future Regulatory Outlook for Zydus
The recall of Chlorpromazine Hydrochloride Tablets, USP 10 mg, is currently classified as 'Ongoing,' indicating that Zydus Pharmaceuticals (USA) Inc. is actively managing the recall process and is expected to implement corrective and preventive actions (CAPA). For regulatory affairs and supply chain VPs, understanding Zydus's remediation timeline is crucial for forecasting future supply stability. The firm must conduct a thorough investigation into the root cause of the N-Nitroso-Desmethyl Chlorpromazine impurity, implement robust controls to prevent recurrence, and provide comprehensive documentation to the FDA. Inadequate or delayed remediation could lead to further regulatory actions, including potential Warning Letters, import alerts for the Baddi, India manufacturing facility, or even consent decrees. The FDA will likely monitor Zydus's response closely, potentially including follow-up inspections. This uncertainty means that procurement teams cannot assume a swift return to normal supply from Zydus for this product. Diversification of sourcing and continuous monitoring of Zydus's regulatory status will be essential to mitigate ongoing business risk and ensure patient access to Chlorpromazine Hydrochloride.